IK channel antagonists represent a novel first in class anti-inflammatory treatment in inflammatory bowel disease (IBD). In preclinical colitis models selective IK channel antagonists (including AN346) have demonstrated robust pharmacological effect in different species. T-cell activity is regulated by modulation of IK channels that are up-regulated in activated T cells and generate the driving force during activation and proliferation of T-helper cells. Blocking IK channels is therefore a novel potential therapeutic strategy for the treatment of peripheral autoimmune/inflammatory indications such as IBD, rheumatoid arthritis, fibrosis and central neuro-inflammatory diseases such as multiple sclerosis. The program is in the late drug discovery phase.